Education
About Us
Working with TipRanks
Follow Us
Azenta (AZTA)
NASDAQ:AZTA
AZTA Stock Chart & Stats
$35.05
-$0.47(-0.91%)
At close: 4:00 PM EST
$35.05
-$0.47(-0.91%)
Day’s Range― - ―
52-Week Range$23.91 - $55.64
Previous CloseN/A
Volume88.55K
Average Volume (3M)587.59K
Market Cap
$1.38B
Enterprise Value$1.14B
Total Cash (Recent Filing)$340.92M
Total Debt (Recent Filing)$51.24M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Feb 11, 2026EPS Estimate
0.14Last Dividend Ex-Date
Dec 02, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding45,839,730
10 Day Avg. Volume463,449
30 Day Avg. Volume587,594
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda26.25
Forecast
1Y Price Target
$37.33Price Target Upside6.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAZTA's recent and ongoing investments could help accelerate growth over the next few years while still allowing for further margin improvement.
Investor RelationsAZTA is hosting an Investor Day in Indianapolis, IN, where management is expected to provide an update on its strategy and FY28 financial targets that could be above Street estimates.
Revenue And ProfitabilityFY25 revenues beat expectations with record Multiomics revenues in the fourth quarter, driven by strength in specific areas such as sequencing volume growth and gene synthesis.
Bears Say
Macroeconomic ImpactThe government shutdown and macroeconomic factors have contributed to a slowdown in bookings and capital expenditure decisions, negatively impacting certain revenues.
Revenue MissFQ3 total revs of $144M missed consensus $149M largely due to geo-driven slowdown in both storage and gene synthesis segments.
Sector ExposureThe academic and government sector, which is about 20% of the mix, is likely to remain an overhang.
Azenta News
AZTA FAQ
What was Azenta’s price range in the past 12 months?
Azenta lowest stock price was $23.91 and its highest was $55.63 in the past 12 months.
What is Azenta’s market cap?
Azenta’s market cap is $1.38B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Feb 11, 2026 which is in 65 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Nov 21, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.02.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta pays a Quarterly dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Azenta dividends here
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.14.
How many shares outstanding does Azenta have?
Azenta has 45,839,730 shares outstanding.
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of $0.21 in its last earnings report, beating expectations of $0.19. Following the earnings report the stock price went up 16.3%.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in AZTA
Azenta Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.33 (6.50% Upside)
$37.33 (6.50% Upside)
Hedge Fund Trend
Decreased
By 397.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.47%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
-13.09%
Trailing 12-Months
Company Description
Azenta
Azenta (AZTA) is a leading provider of life sciences solutions, specializing in sample management and genomic services. The company operates primarily in the biotechnology and pharmaceutical sectors, offering a range of services that include biobanking, sample storage, and genomic analysis. Azenta's core products and services are designed to support researchers and organizations in advancing their scientific endeavors, particularly in drug development and personalized medicine.
AZTA Company Deck
AZTA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Azenta, Inc. demonstrated resilience amidst a challenging macroeconomic environment, achieving revenue growth and margin expansion. The company reported record performance in its Multiomics segment and maintained a strong cash position. However, macroeconomic challenges and specific segment weaknesses, such as in Sanger sequencing and automated storage, were notable concerns. The company remains optimistic about its growth prospects in fiscal 2026, with anticipated revenue growth and margin expansion.View all AZTA earnings summariesAZTA Stock 12 Month Forecast
Average Price Target
$37.33
▲(6.50% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---